Previous Close | 9.55 |
Open | 9.37 |
Bid | 9.14 x 100 |
Ask | 9.75 x 100 |
Day's Range | 9.01 - 9.50 |
52 Week Range | 3.69 - 44.56 |
Volume | |
Avg. Volume | 437,559 |
Market Cap | 11.421M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.46 |
Earnings Date | Mar 28, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Mar 15, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for MEDS
TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced that the Company’s board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company’s web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on
TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”). On November 21, 2023, the Company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q,
TAMPA, FL, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of a pharmaceutical business-to-business exchange platform, announced today that it received a notice of non-compliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) on November 21, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), the Company is n